You are here

  • Home
  • Archive
  • Volume 80, Issue 2
  • Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study

Article metrics

Article menu
Download PDFPDF
Letter
Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study

 

Online download statistics by month:

Online download statistics by month: July 2020 to April 2025

AbstractFullPdf
Jul 202014141401411
Aug 2020406404119
Sep 202034128775
Oct 202023324575
Nov 202014114258
Dec 202015315365
Jan 2021499485129
Feb 202129528894
Mar 202119419480
Apr 202116516552
May 202113813758
Jun 202112811940
Jul 202111310333
Aug 202115112980
Sep 2021998538
Oct 202111910552
Nov 2021907332
Dec 2021605312
Jan 2022816621
Feb 202210710215
Mar 2022756617
Apr 2022565313
May 2022695919
Jun 2022555214
Jul 202250418
Aug 2022979013
Sep 2022524712
Oct 2022504817
Nov 2022464214
Dec 202239367
Jan 2023524822
Feb 2023655913
Mar 2023575413
Apr 20233622
May 20235721
Jun 20233300
Jul 20235620
Aug 20239911
Sep 202363211
Oct 20236012
Nov 20235021
Dec 20234711
Jan 20244141
Feb 20242532
Mar 20246133
Apr 20248130
May 20243132
Jun 20243953
Jul 20245522
Aug 20245000
Sep 202411812
Oct 202416642
Nov 202423695
Dec 20247131
Jan 202514622
Feb 20253040
Mar 2025420
Apr 2025100
Total734654921765